1,974 Shares in Abbott Laboratories (NYSE:ABT) Acquired by Austin Private Wealth LLC

Austin Private Wealth LLC purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,974 shares of the healthcare product maker’s stock, valued at approximately $217,000.

Several other large investors have also recently made changes to their positions in ABT. Patriot Investment Management Group Inc. lifted its stake in shares of Abbott Laboratories by 3.1% during the 4th quarter. Patriot Investment Management Group Inc. now owns 3,236 shares of the healthcare product maker’s stock worth $356,000 after acquiring an additional 96 shares during the last quarter. Shepherd Financial Partners LLC lifted its position in shares of Abbott Laboratories by 4.5% during the fourth quarter. Shepherd Financial Partners LLC now owns 2,275 shares of the healthcare product maker’s stock worth $250,000 after purchasing an additional 99 shares during the last quarter. Stonebridge Capital Advisors LLC boosted its stake in shares of Abbott Laboratories by 0.5% during the first quarter. Stonebridge Capital Advisors LLC now owns 20,029 shares of the healthcare product maker’s stock valued at $2,371,000 after purchasing an additional 100 shares during the period. Landaas & Co. WI ADV grew its holdings in shares of Abbott Laboratories by 1.8% in the fourth quarter. Landaas & Co. WI ADV now owns 5,534 shares of the healthcare product maker’s stock worth $608,000 after purchasing an additional 100 shares during the last quarter. Finally, Renaissance Investment Group LLC increased its stake in Abbott Laboratories by 0.7% in the 4th quarter. Renaissance Investment Group LLC now owns 14,204 shares of the healthcare product maker’s stock worth $1,563,000 after buying an additional 100 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Andrea F. Wainer sold 42,500 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $112.50, for a total value of $4,781,250.00. Following the completion of the sale, the executive vice president now directly owns 65,027 shares of the company’s stock, valued at $7,315,537.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Abbott Laboratories news, EVP Andrea F. Wainer sold 42,500 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $112.50, for a total value of $4,781,250.00. Following the completion of the sale, the executive vice president now owns 65,027 shares in the company, valued at $7,315,537.50. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Andrea F. Wainer sold 12,500 shares of Abbott Laboratories stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the executive vice president now directly owns 78,704 shares in the company, valued at $9,444,480. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,435 shares of company stock worth $6,451,298. Corporate insiders own 1.10% of the company’s stock.

Abbott Laboratories Stock Up 0.1 %

NYSE ABT traded up $0.16 during trading hours on Thursday, hitting $113.64. 5,278,016 shares of the company were exchanged, compared to its average volume of 5,747,185. The company has a 50 day moving average of $115.13 and a two-hundred day moving average of $106.42. The firm has a market cap of $197.19 billion, a price-to-earnings ratio of 34.94, a PEG ratio of 2.68 and a beta of 0.75. Abbott Laboratories has a 52-week low of $89.67 and a 52-week high of $121.64. The company has a quick ratio of 1.16, a current ratio of 1.64 and a debt-to-equity ratio of 0.35.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $1.19 EPS for the quarter, meeting analysts’ consensus estimates of $1.19. The company had revenue of $10.24 billion for the quarter, compared to the consensus estimate of $10.19 billion. Abbott Laboratories had a net margin of 14.27% and a return on equity of 20.65%. The company’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.03 EPS. Equities research analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 1.94%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s payout ratio is 67.48%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Raymond James raised their target price on shares of Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Barclays raised their price target on Abbott Laboratories from $133.00 to $141.00 and gave the company an “overweight” rating in a research note on Friday, January 26th. Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $116.00 to $121.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 13th. TheStreet raised shares of Abbott Laboratories from a “c+” rating to a “b-” rating in a report on Thursday, December 21st. Finally, Citigroup increased their price target on shares of Abbott Laboratories from $123.00 to $126.00 and gave the stock a “buy” rating in a report on Thursday, January 25th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $120.00.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.